We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Exemestaneis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Exemestane studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2003–2022 with a typical study size of 7,030 participants.
Based on 7 studies · 2 meta-analyses · 5 RCTs · 33,699 total participants
Confidence
HighBy outcome
Exemestane has an evidence score of 4.9/10 — emerging evidence based on 7 indexed studies, including 2 meta-analyses. A steroidal, irreversible ('suicide') aromatase inhibitor (Aromasin) approved for hormone-receptor-positive breast cancer, where its evidence is strong (the IES switch trial, MAP.3 prevention, and head-to-head with anastrozole in MA.27). It is the steroidal counterpart to anastrozole and letrozole, and because its metabolite is mildly androgenic it is sometimes claimed to spare bone — but the trials show it still lowers bone-mineral density and raises fracture risk. Used off-label in men to lower estradiol and raise testosterone, a small crossover RCT confirms it does shift the hormones, but estrogen is required for the male skeleton and lipids. A prescription drug, not a supplement, and NOT a longevity drug. Representative study: PMID 35123662.
The commonly studied dose of Exemestane is Approved breast-cancer dose is 25 mg once daily with food. Off-label use in men typically uses lower or intermittent dosing (e.g. 12.5-25 mg every other day to a few times weekly) under a clinician, titrated to estradiol and testosterone with bone monitoring. A prescription drug; not an approved men's-health regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Testosterone (TRT)
Mostly mechanism / observationalThe primary male androgen and an FDA-approved prescription drug for diagnosed male hypogonadism — and a Schedule III CONTROLLED SUBSTANCE. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only; non-medical, supraphysiologic, and 'anti-aging' use is illegal and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Exemestane (Aromasin) — steroidal, irreversible aromatase inhibitor
A steroidal, irreversible ('suicide') aromatase inhibitor (Aromasin) approved for hormone-receptor-positive breast cancer, where its evidence is strong (the IES switch trial, MAP.3 prevention, and head-to-head with anastrozole in MA.27). It is the steroidal counterpart to anastrozole and letrozole, and because its metabolite is mildly androgenic it is sometimes claimed to spare bone — but the trials show it still lowers bone-mineral density and raises fracture risk. Used off-label in men to lower estradiol and raise testosterone, a small crossover RCT confirms it does shift the hormones, but estrogen is required for the male skeleton and lipids. A prescription drug, not a supplement, and NOT a longevity drug.
Exemestane has strong, multi-trial evidence in its approved indications — the IES switch trial, the TEAM monotherapy trial, head-to-head equivalence with anastrozole in MA.27, and a 65% reduction in invasive breast cancer in the MAP.3 prevention trial — and a small crossover RCT confirms it lowers estradiol and raises testosterone in men. But the off-label male use is unproven for any functional outcome, its 'bone-sparing' reputation does not hold (a TEAM bone meta-analysis showed it decreased spine BMD ~3.5% at 2 years and the EBCTCG meta-analysis found more fractures than tamoxifen), and estrogen is required for the male skeleton and lipids — so the off-label men's-health case stays emerging.
Exemestane (Aromasin) is a steroidal, irreversible aromatase inhibitor — a 'suicide' inhibitor that binds the aromatase (CYP19A1) enzyme covalently and permanently inactivates it, unlike the reversible non-steroidal inhibitors anastrozole and letrozole.
Aromatase converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone), so blocking it lowers circulating estrogen.
Its approved, evidence-rich use is in postmenopausal hormone-receptor-positive breast cancer: the landmark Intergroup Exemestane Study (IES) showed that switching to exemestane after two to three years of tamoxifen significantly improved disease-free survival versus completing five years of tamoxifen; the MA.27 phase III trial found exemestane neither superior nor inferior to anastrozole as up-front adjuvant therapy; the TEAM trial established exemestane monotherapy as an appropriate option; and the MAP.3 trial (Goss, NEJM 2011) showed exemestane reduced the incidence of invasive breast cancer by 65% in postmenopausal women at elevated risk — a genuine chemoprevention result.
Everything else is off-label.
Because exemestane is a steroid and its principal metabolite (17-hydroxyexemestane) is mildly androgenic, it has been marketed as the 'bone-sparing' aromatase inhibitor — but that claim does not hold up: a meta-analysis of the TEAM bone sub-studies showed exemestane DECREASED lumbar-spine bone-mineral density by ~3.5% at two years while tamoxifen INCREASED it, and the EBCTCG patient-level meta-analysis recorded significantly more fractures on aromatase inhibitors than tamoxifen.
In men, the same mechanism shifts the testosterone/estradiol balance: a small randomized crossover study in healthy young men showed exemestane suppressed estradiol by ~38% with a reciprocal ~60% rise in testosterone, which is why it is reached for off-label in TRT-adjacent and bodybuilding contexts.
The crucial honesty gate: estrogen is not just a 'female' hormone — in men estradiol is the dominant regulator of bone-mineral density and contributes to lipid and cardiovascular health, so chronically suppressing it risks bone loss and adverse lipids exactly as it does in women.
There are no large trials demonstrating a functional benefit (strength, body composition, hard outcomes) from exemestane in men. Exemestane is a prescription drug; it is approved only for breast cancer, used off-label in men, and is NOT a longevity or healthspan drug.
The score reflects strong evidence in the approved oncology indications (treatment and prevention) and a reliable hormonal effect in men, set against unproven functional benefit off-label and a real, documented bone-density/fracture cost from estrogen suppression.
As a steroidal 'suicide' inhibitor, exemestane binds the aromatase enzyme covalently and permanently inactivates it — lowering estradiol until new enzyme is synthesized, unlike the reversible non-steroidal AIs.
Lower estradiol reduces negative feedback at the hypothalamus and pituitary, raising LH and endogenous testosterone production in men — a reciprocal testosterone rise accompanies the estradiol drop.
Exemestane's principal metabolite (17-hydroxyexemestane) is weakly androgenic, which is why it was proposed to spare bone relative to non-steroidal AIs — but trials show it still lowers BMD.
Estradiol is the dominant regulator of bone-mineral density and contributes to lipids in both sexes; suppressing it lowers BMD and raises fracture risk — the central trade-off of the drug.
How Exemestane works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved breast-cancer dose is 25 mg once daily with food. Off-label use in men typically uses lower or intermittent dosing (e.g. 12.5-25 mg every other day to a few times weekly) under a clinician, titrated to estradiol and testosterone with bone monitoring. A prescription drug; not an approved men's-health regimen.
Take with food
| Form | Type |
|---|---|
| 💊Oral tablet (exemestane 25 mg) | Recommended |
| 💊Anastrozole or letrozole (the reversible non-steroidal AIs); clomiphene (a SERM — raises T without crashing estradiol, often preferred for fertility) | Alternative |
Exemestane is the steroidal, irreversible AI; anastrozole and letrozole are the reversible non-steroidal siblings. Within off-label men's use, SERMs like clomiphene raise testosterone without the same estrogen-suppression bone cost.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Once daily with food (breast cancer) or intermittently (off-label men's use). Monitor estradiol and bone density — estrogen is required for the skeleton in both sexes.
Dose-response data unavailable. The current published research for Exemestane does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In postmenopausal HR-positive breast cancer, switching to exemestane after tamoxifen improved disease-free survival (IES); monotherapy and head-to-head with anastrozole are established options.
In the MAP.3 trial, exemestane reduced the incidence of invasive breast cancer by 65% in higher-risk postmenopausal women.
A randomized crossover study in men showed exemestane lowered estradiol ~38% with a reciprocal ~60% rise in testosterone — but no functional benefit has been demonstrated.
Despite a mildly androgenic metabolite, exemestane decreased spine BMD ~3.5% over 2 years in the TEAM bone sub-studies, and AIs caused more fractures than tamoxifen in the EBCTCG meta-analysis.
Off-label and unproven for strength/body-composition or any functional benefit; monitor estradiol and bone — over-suppression harms the male skeleton and lipids.
Higher fracture risk — estrogen suppression worsens bone despite the steroidal metabolite; weigh carefully and monitor DXA.
Aromatase inhibitors are ineffective in premenopausal women unless combined with ovarian suppression, and are teratogenic — not appropriate outside specialist oncology protocols.
Estrogens directly counteract exemestane's mechanism and would negate its estrogen-lowering effect.
Exemestane is metabolized by CYP3A4; strong inducers lower its exposure and a higher dose may be needed when co-administered.
Tip: Estrogen suppression lowers BMD despite the mildly androgenic metabolite; monitor DXA, ensure calcium/vitamin D, consider bone agents. Avoid over-suppressing estradiol.
Tip: A well-known aromatase-inhibitor effect (musculoskeletal symptoms were the most common in TEAM); usually manageable, occasionally limits adherence.
Tip: A direct consequence of low estrogen; usually tolerable and reversible on stopping.
Tip: Crashing estradiol in men harms libido and mood; keep E2 in a healthy range rather than as low as possible.
The best time to take Exemestane is with meals. Take it with food. Bioavailability is increased ~40% when taken after a meal, so the approved 25 mg dose is taken with food.
Exemestane should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are bone-density loss / increased fracture risk, joint / muscle aches (arthralgia), hot flushes / fatigue. Use caution if any of these apply to you: Premenopausal women / pregnancy (teratogenic; approved only postmenopausal); Pre-existing osteoporosis or high fracture risk (estrogen suppression worsens bone); Hypersensitivity to exemestane.
Tamoxifen (Nolvadex)
Mostly mechanism / observationalA selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug.
Often co-prescribed to offset aromatase-inhibitor-driven bone loss — a clinically relevant interaction to plan around, not avoid.